MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company’s sustainability activities, performance, and results from the last three years.
“We are proud to issue our first annual Sustainability Report, showing our commitment to corporate sustainability initiatives and enhanced disclosures,” stated Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences. He continued, “While we are still early in our sustainability journey, we believe it is important to embrace sustainable, responsible business practices as we deliver on our mission to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.”
The Sustainability Report includes:
Environmental Initiatives: Details of Sight Sciences’ efforts to reduce its environmental footprint through energy efficiency, waste reduction, and sustainable practices, including reporting on our supplier standards and ethical research and development measures.
Social Responsibility: Insights into Sight Sciences’ initiatives to support community engagement, diversity, equity, and inclusion, and employee well-being, including reporting on employee diversity and equity measures, health and safety measures, and voluntary employee turnover.
Governance Practices: Disclosure of Sight Sciences’ governance framework, ethical standards, and commitment to transparency and accountability, including reporting on information security breaches.
Key Highlights from the Sustainability Report:
- From 2021 through 2023, we supported 25 indigent care programs in over 10 countries.
- As of December 31, 2023, we employed 214 people worldwide, with nearly 50% of our workforce comprised of women.
- In 2023, we launched a Women in Leadership initiative to encourage, support, and empower women to take on leadership roles.
- As of December 31, 2023, four of our eight board members are women, and we are committed to having no less than 40% female representation on the board.
- We have adopted a Stock Ownership Policy applicable to our executive officers and non-employee directors that is intended to align the interests of our executive officers and directors with those of our stockholders.
- To reduce our impact on the environment, in the first quarter of 2023 we reduced our use of weekly air freight shipments and consolidated shipping to fewer monthly or bimonthly shipments using sea freight.
For additional information and highlights, please see the full Sustainability Report, which can be found here. All Environmental, Social, and Governance (“ESG”) practices are overseen by the Company’s Nominating and Corporate Governance committee.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. Glaucoma is the world’s leading cause of irreversible blindness, and the Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE-marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2024 Sight Sciences. All rights reserved.
Media contact:
pr@SightSciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
